Skip to content

Released Nov 7, 2023, after the close

10-Q filed Nov 7, 2023, 38 days after period end · 0000950170-23-060385

Q3 2023 · 10-Q
Revenue$25.37M−1.1% vs Q3 2022−8.3% vs Q2 2023
Net Income-$21.00MN/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.27N/M vs Q3 2022N/M vs Q2 2023
Gross Profit$11,154,000+21.0%
Operating Income-$21,172,000N/M
Operating Cash Flowderived-$11,412,000N/M
Free Cash Flowderived-$12,317,000N/M
Margins · derived
Gross margin44.0%+8.0 pt vs Q3 2022
Operating margin-83.5%+29.7 pt vs Q3 2022
Net margin-82.8%+32.0 pt vs Q3 2022

What the release said

The release

Same quarter

MetricQ3 2023Q3 2022Q3 2021Q3 2020
Revenue$25.37M$25.65M$28.50M$39.86M
Net Income-$21.00M-$29.43M-$13.84M-$6.00M
EPS Diluted-$0.27-$0.37-$0.18-$0.08

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR